"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease

Soutien aux Actions contre les Maladies du Globule Rouge355 enrolled

Overview

To describe change in ACR and eGFR during study follow-up, and assesss the association of baseline and change in ACR and eGFR, with progression of kidney failure and/or all-cause mortality.

This is a retrospective, non-interventional, secondary use of the data coming from the single-center secondary GEN-MOD study cohort at the Henri Mondor Hospital (Creteil, France). The GEN-MOD cohort includes 355 SCD patients. The GEN-MOD data are accessible through the center's clinical and laboratory database and will be extracted and analyzed for the purpose of this study. The enrolment in the GEN-MOD cohort lasted from 01 December 2002 until 01 March 2014. Follow-up occurred every six months and ranged from five to seventeen years and ended on 31 December 2019. The index date (baseline) for this study is the time of inclusion of patients in GEN-MOD cohort study

Study Type

OBSERVATIONAL

Enrollment

355

Conditions

Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate Progression of Kidney Failure and or All-cause Mortality

Interventions

no intervention studyOTHER

no intervention study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults aged ≥ 18 years old. * Confirmed diagnosis of SCD by Hb electrophoresis or high performance liquid chromatography. SCD genotypes HbSS, HbSβ0-thal. * Availability of ACR and eGFR baseline records. Exclusion Criteria: * Patients enrolled in a chronic transfusion program. * Patients receiving hydroxyurea treatment at the time of study enrollment.

Locations (1)

Henri Mondor Hospital

Créteil, France

Outcomes

Primary Outcomes

Change in albumin to creatinine(ACR) and glomerular filtration rate(eGFR)

To describe change in ACR and eGFR during study follow-up, and assesss the association of baseline and change in ACR and eGFR, with progression of kidney failure and/or all-cause mortality

Time frame: 10 years

Secondary Outcomes

Progression of kidney dysfunction

•To assess the association of baseline and change in ACR, and CKD progression category

Time frame: 10 years

Change in ACR

To assess potential risk factors (at baseline) for ACR elevation during study follow-up

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.